CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy

Sponsor
Liping Dou
Study ID
NCT07779018
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • CD22/CD19 CAR-T cell immunotherapy — DRUG
    Patients who achieved complete response (CR) after standard second-line chemotherapy will receive CD19/CD22 CAR-T cell immunotherapy as consolidation treatment. Autologous T cells will be collected and genetically modified to express chimeric antigen receptors targeting CD19 and CD22. Following lymphodepleting chemotherapy, patients will receive a single intravenous infusion of CD19/CD22 CAR-T cells.

Study Details

The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.

Key Dates

First listed
Aug 21, 2026
Start date
Apr 1, 2026
Status verified
Apr 2026
Primary completion
Apr 1, 2027
Completion
Mar 1, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CD19/CD22 CAR-T cell immunotherapy treatment

Primary Outcome Measure

1-year progression free survival rate (1-year-PFSR) [ Time Frame: 1 year after treatment ]

Central Contacts

Related Studies